| The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and … MJ Millan, A Gobert, F Lejeune, A Dekeyne, A Newman-Tancredi, ... Journal of Pharmacology and Experimental Therapeutics 306 (3), 954-964, 2003 | 726 | 2003 |
| Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and … MJ Millan, L Maiofiss, D Cussac, V Audinot, JA Boutin, ... Journal of Pharmacology and Experimental Therapeutics 303 (2), 791-804, 2002 | 544 | 2002 |
| Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and … A Gobert, JM Rivet, F Lejeune, A Newman‐Tancredi, ... Synapse 36 (3), 205-221, 2000 | 393 | 2000 |
| Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study A Newman-Tancredi, S Gavaudan, C Conte, C Chaput, M Touzard, ... European journal of pharmacology 355 (2-3), 245-256, 1998 | 281 | 1998 |
| Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal … A Gobert, JM Rivet, V Audinot, A Newman-Tancredi, L Cistarelli, MJ Millan Neuroscience 84 (2), 413-429, 1998 | 262 | 1998 |
| P5-HT1A receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function AL Garcia-Garcia, A Newman-Tancredi, ED Leonardo Psychopharmacology 231, 623-636, 2014 | 243 | 2014 |
| Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes A Newman-Tancredi, D Cussac, Y Quentric, M Touzard, L Verrièle, ... Journal of Pharmacology and Experimental Therapeutics 303 (2), 815-822, 2002 | 223 | 2002 |
| Agonist and antagonist actions of yohimbine as compared to fluparoxan at α2‐adrenergic receptors (AR)s, serotonin (5‐HT)1A, 5‐HT1B, 5‐HT1D and dopamine D2 and D3 receptors … MJ Millan, A Newman‐Tancredi, V Audinot, D Cussac, F Lejeune, ... Synapse 35 (2), 79-95, 2000 | 221 | 2000 |
| Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and … A Newman-Tancredi, D Cussac, V Audinot, JP Nicolas, F De Ceuninck, ... Journal of Pharmacology and Experimental Therapeutics 303 (2), 805-814, 2002 | 210 | 2002 |
| Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2‐adrenergic and serotonin2C receptors: a … MJ Millan, A Gobert, JM Rivet, A Adhumeau‐Auclair, D Cussac, ... European Journal of Neuroscience 12 (3), 1079-1095, 2000 | 207 | 2000 |
| Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties A Newman-Tancredi, MS Kleven Psychopharmacology 216 (4), 451-473, 2011 | 196 | 2011 |
| Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies L Bardin, N Malfetes, A Newman-Tancredi, R Depoortere Behavioural brain research 205 (2), 360-366, 2009 | 181 | 2009 |
| The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. A Newman-Tancredi Current opinion in investigational drugs (London, England: 2000) 11 (7), 802-812, 2010 | 177 | 2010 |
| S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine … MJ Millan, A Gobert, F Lejeune, A Newman-Tancredi, JM Rivet, A Auclair, ... Journal of Pharmacology and Experimental Therapeutics 298 (2), 565-580, 2001 | 164 | 2001 |
| S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT … LG Millan MJ, Gobert A, Newman-Tancredi A, Audinot V J Pharmacol Exp Ther. 286 (3), 1341-55., 1998 | 162* | 1998 |
| Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist,(+)-S 14297: 1. Activation of postsynaptic D3 … MJ Millan, JL Peglion, J Vian, JM Rivet, M Brocco, A Gobert, ... Journal of Pharmacology and Experimental Therapeutics 275 (2), 885-898, 1995 | 159 | 1995 |
| International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function NM Barnes, GP Ahern, C Becamel, J Bockaert, M Camilleri, ... Pharmacological reviews 73 (1), 310-520, 2021 | 157 | 2021 |
| Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5‐HT2A sites for PCP … MJ Millan, M Brocco, A Gobert, F Joly, K Bervoets, JM Rivet, ... European Journal of Neuroscience 11 (12), 4419-4432, 1999 | 157 | 1999 |
| Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia A Newman-Tancredi, MB Assié, N Leduc, AM Ormière, N Danty, C Cosi International Journal of Neuropsychopharmacology 8 (3), 341-356, 2005 | 156 | 2005 |
| A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3 Receptor Antagonists (+)-S 14297, Nafadotride, GR103,691 and U99194 V Audinot, A Newman-Tancredi, A Gobert, JM Rivet, M Brocco, F Lejeune, ... Journal of Pharmacology and Experimental Therapeutics 287 (1), 187-197, 1998 | 156 | 1998 |
CUSSAC Didier, PhDCussac ConsultingVerified email at cussac-consulting.com
